Last reviewed · How we verify
RAK therapy
RAK therapy is a regenerative medicine approach that uses autologous bone marrow-derived cells to promote tissue repair and regeneration.
RAK therapy is a regenerative medicine approach that uses autologous bone marrow-derived cells to promote tissue repair and regeneration. Used for Osteoarthritis and joint degeneration, Tissue repair and regeneration.
At a glance
| Generic name | RAK therapy |
|---|---|
| Also known as | rabeprazole, amoxicillin, clarithromycin |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | Cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
RAK (Regenerative Autologous Kinetic) therapy involves harvesting and processing a patient's own bone marrow cells, which are then administered to damaged or degenerative tissues to stimulate healing and regeneration. The mechanism relies on the immunomodulatory and regenerative properties of bone marrow stem cells and progenitor cells to reduce inflammation and promote tissue repair.
Approved indications
- Osteoarthritis and joint degeneration
- Tissue repair and regeneration
Common side effects
- Injection site pain or swelling
- Temporary inflammation
Key clinical trials
- The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial (PHASE2)
- RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention (NA)
- Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases (EARLY_PHASE1)
- Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAK therapy CI brief — competitive landscape report
- RAK therapy updates RSS · CI watch RSS
- Kaohsiung Medical University Chung-Ho Memorial Hospital portfolio CI